Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ACLY | P53396 | 2/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19227950 | 0.86 | ALDH1A1 (0.37) | ALDH1A1MEN1CYP1A2KMT2AFFAR3 | |
| SCHEMBL19607726 | 0.86 | FFAR3 (0.37) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL29186815 | 0.83 | FFAR3 (0.35) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL6902951 | 0.77 | CES2 (0.39) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL4384467 | 0.75 | FAAH (0.32) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Lithium Ion SCHEMBL25327835 | 0.73 | — | — | |
| SCHEMBL5566630 | 0.73 | CES2 (0.30) | — | |
| SCHEMBL16681682 | 0.72 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL7622632 | 0.72 | SOAT1 (0.41) | ALDH1A1MEN1THRBKMT2A | |
| SCHEMBL19582468 | 0.70 | CES2 (0.37) | ALDH1A1MEN1CYP1A2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108218702-B | Preparation method of 2-fluoro ethyl acetoacetate | 湖北卓熙氟化股份有限公司 | 2020-10-09 | — | — | CN | claimed |
| CN-108218702-B | Preparation method of 2-fluoro ethyl acetoacetate | 湖北卓熙氟化股份有限公司 | 2020-10-09 | — | — | CN | disclosed |
| US-10112973-B2 | Process for the preparation of ramipril | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2018-10-30 | — | — | US | disclosed |
| EP-3154940-B1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2018-04-18 | — | — | EP | disclosed |
| EP-2549991-B1 | FE(III) COMPLEX COMPOUNDS FOR TREATING AND PROPHYLAXIS FOR ANAEMIA SYMPTOMS AND ANAEMIA | VIFOR (INTERNATIONAL) AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20170158733-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2017-06-08 | — | — | US | disclosed |
| EP-3154940-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | Sanofi-Aventis Deutschland GmbH (DE) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189108-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-12-17 | — | — | WO | disclosed |
| EP-2549991-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | Vifor (International) AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117225-A1 | FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS | VIFOR (INTERNATIONAL) AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20050007872-A1 | Microdevice | FUJI PHOTO FILM CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1481724-A1 | Reaction method using microreactor | Fuji Photo Film Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1481723-A1 | Microdevice | Fuji Photo Film Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1095928-B1 | Direct fluorination process for preparing high purity alpha-fluoro-beta-dicarbonyl compounds | AIR PROD & CHEM (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6455728-B1 | REACTING METHYL-3-OXOPENTANOATE WTIH HYDROGEN FLUORIDE IN PRESENCE OF OXYGEN; BY-PRODUCT INHIBITION; CHEMICAL INTERMEDIATES FOR PRODUCING PHARMACEUTICALS | AIR PRODUCTS AND CHEMICALS, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-0996606-B1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 CHEMICALS LTD (GB) | 2002-01-16 | — | — | EP | disclosed |
| US-6300511-B1 | FLUORINATING CARBONYL COMPOUND BY REPLACEMENT OF ALPHA-HYDROGEN ATOM WITH FLUORINE COMPRISING REACTING COMPOUND WITH FLUORINATING AGENT IN PRESENCE OF CATALYTICALLY EFFECTIVE AMOUNT OF TRANSITION METAL-CONTAINING CATALYST | F2 CHEMICALS LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| EP-1095928-A2 | Direct fluorination process for preparing high purity alpha-fluoro-beta-dicarbonyl compounds | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0996606-A1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 Chemicals Ltd. (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999003802-A1 | CATALYSED FLUORINATION OF CARBONYL COMPOUNDS | F2 CHEMICALS LIMITED (GB) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112973-B2 | Process for the preparation of ramipril | CYP2S1, CYP3A5, CYP4B1 | ALDH1A1 162/4885MEN1 4797/4885CYP1A2 4/4885 |
| US-20170158733-A1 | PROCESS FOR THE PREPARATION OF RAMIPRIL | CYP2S1, CYP3A5, CYP4B1 | ALDH1A1 162/4885MEN1 4797/4885CYP1A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.